Skip to main content
Premium Trial:

Request an Annual Quote

SeekIn Gets CE Mark for Leukemia Molecular Karyotyping Kit

NEW YORK — SeekIn said on Thursday that it has received CE marking for its LeukoPrint Molecular Karyotyping Kit for the diagnosis and stratification of leukemia patients.

LeukoPrint uses shallow whole-genome sequencing to identify copy number aberrations (CNA) in blood samples from leukemia patients to assist in diagnostic classification and risk stratification.

"LeukoPrint provides a cost-effective and simplified method for prompt and accurate CNA profiling in leukemia patients … [using] a standardized protocol which can be readily extended to clinical laboratories worldwide," SeekIn Founder and CEO Mao Mao said in a statement. By detecting CNAs of short DNA fragments and incorporating that with routine diagnostic methods, LeukoPrint can benefit conventional cytogenetics by improving diagnostic yield, Mao added.

Earlier this year, Shenzhen, China-based SeekIn received the CE mark for its SeekInCare Cancer Detection Kit for early cancer detection.